Cumberland Pharma's Caldolor expected to qualify for separate Medicare reimbursement under NOPAIN Act from 2025

CUMBERLAND PHARMACEUTICALS INC

NOPAIN Act requires Medicare to provide separate reimbursement for non-opioid pain management products in outpatient hospital and ambulatory surgical center settings.
Caldolor (ibuprofen injection) is a non-opioid analgesic indicated for pain management, shown to reduce opioid use.
Reimbursement applies to products furnished between Jan 1, 2025 and Jan 1, 2028; CMS to issue regs in 2024.
Caldolor is FDA approved for mild to severe pain in adults and pediatric patients age 6 months+.
Company expects this will positively impact Caldolor's Medicare reimbursement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.